Hillhouse Investment Management, Ltd.'s Form 4 filing
ArriVent BioPharma, Inc.AVBP · filed Feb 3, 2026
- Accession no.
- 0000902664-26-000675
- Filed
- Feb 3, 2026, 4:05 PM ET
- Trade date
- Dec 10, 2025
- Filing delay
- 55 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $13.0M. It was filed 55 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hillhouse Investment Management, Ltd.CIK 0001510589 | 10% Owner |
| HHLR Advisors, Ltd.CIK 0001762304 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | Common Stock | SSaleDisposed | −555,555 | $23.37 | −$12,983,320.35 | 3,929,117 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.